Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PhaseBio Pharmaceuticals Inc (PHAS)
|
Add to portfolio |
|
|
|
| Price: |
$2.56
| | Metrics |
| OS: |
49.9
|
M
| |
|
|
| Market cap: |
$128
|
M
| |
-706
|
% ROIC
|
|
Net cash:
|
$3.73
|
M
| |
$0.07
|
per share
|
|
EV:
|
$124
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($102)
|
M
| |
|
|
|
EBIT
|
($104)
|
M
| |
|
|
| EPS |
($2.21)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 10.8 | 0.3 | 2.4 | 0.7 | 0.0 | 7.4 |
| Revenue growth | 3284.7% | -86.4% | 253.4% | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.5 |
| Gross profit | 10.8 | 0.3 | 2.4 | 0.7 | 0.0 | -2.1 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | | -28.8% |
| Research and development | 102.1 | 72.1 | 30.9 | 15.5 | 6.2 | |
| General and administrative | 16.1 | 13.1 | 11.2 | 4.9 | 2.3 | 2.1 |
| EBIT | -107.4 | -84.9 | -39.7 | -19.6 | -8.5 | -9.5 |
| EBIT margin | -991.2% | -26517.5% | -1683.0% | -2940.7% | | -128.8% |
| Pre-tax income | -129.5 | -98.6 | -39.2 | -23.8 | -10.2 | -9.2 |
| Income taxes | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -131.1 | -98.6 | -39.2 | -23.8 | -10.2 | -9.2 |
| Net margin | -1210.1% | -30801.6% | -1662.3% | -3569.8% | | -125.0% |
| |
| Diluted EPS | ($2.98) | ($3.39) | ($1.43) | ($4.49) | ($13.78) | ($12.41) |
| Shares outstanding (diluted) | 43.9 | 29.1 | 27.5 | 5.3 | 0.7 | 0.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|